I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

ROCKVILLE, Md. , Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.

C. Wainwright 26th Annual Global Investment Conference on September 10, 2024 . H.

C. Wainwright 26th Annual Global Investment Conference The webcast will also be available under "Event Calendar" on I-Mab's IR website at https://ir.i-mabbiopharma.

com/ For more information, please contact your H.C. Wainwright representative.

About I-Mab I-Mab (NASDAQ: IMAB ) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland . For more information, please visit https://www.

i-mabbiopharma.com and follow us on LinkedIn and X. For more information, please contact: Tyler Ehler Senior Director, Investor Relations [email protected] SOURCE I-Mab Biopharma.